Literature DB >> 8828632

Vitamin B12 deficiency in adolescents and young adults with phenylketonuria.

W B Hanley1, A S Feigenbaum, J T Clarke, W E Schoonheyt, V J Austin.   

Abstract

Following several years absence from clinical follow up, an 18-year-old female on diet therapy for phenylketonuria presented with spastic paraparesis, tremor, disorientation, slurred speech, distractibility, deteriorating mental function and megaloblastic anaemia (Hb 64g/l mean corpuscular volume 121). Plasma phenylalanine levels were 100-600 mumol/l for the first 18 months of life but thereafter, because of serious psycho-social factors, > 1200 mumol/l. Her diet had strictly excluded all meats, eggs and dairy products but she had been ingesting her medical food (Lofenalac) only irregularly. Further investigation revealed a vitamin B12 level of 65.8 pmol/l (normal 150-670). Treatment with oral B12 quickly corrected her anaemia and there was a gradual improvement in speech, gait, tremor, disorientation and mood but mild spastic diplegia remained. This case prompted us to survey 37 adolescent and young adult phenylketonuria patients in our clinic -28 were on diet therapy, 9 were off (age 11-35 years, mean 21.6 years, 17 males, 20 females). Those on diet were not under ideal metabolic control. Six (16%) had subnormal serum B12 levels (< 150 pmol/l) and another six had borderline low values (150-200 pmol/l). None had specific neurological signs of subacute combined degeneration. Serum methylmalonic acid and homocysteine were not measured. On the basis of this survey we recommend that complete blood count, serum B12, RBC folate, methylmalonic acid and homocysteine be routinely measured in adolescents and young adults with phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8828632     DOI: 10.1007/pl00014233

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria).

Authors:  R S PAINE
Journal:  Pediatrics       Date:  1957-08       Impact factor: 7.124

2.  Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register.

Authors:  I Smith; M G Beasley; O H Wolff; A E Ades
Journal:  J Pediatr       Date:  1988-03       Impact factor: 4.406

3.  The value of the erythrocyte indices as a screening procedure in predicting nutritional deficiencies.

Authors:  S D O Broin; B P Kelleher; S R McCann; R J Ryder; J M Scott
Journal:  Clin Lab Haematol       Date:  1990

4.  Spasticity and white matter abnormalities in adult phenylketonuria.

Authors:  P A McCombe; D B McLaughlin; J B Chalk; N N Brown; J J McGill; M P Pender
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

5.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

6.  Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis.

Authors:  J Lindenbaum; E B Healton; D G Savage; J C Brust; T J Garrett; E R Podell; P D Marcell; S P Stabler; R H Allen
Journal:  N Engl J Med       Date:  1988-06-30       Impact factor: 91.245

7.  The natural history of untreated phenylketonuria over 20 years.

Authors:  D B Pitt; D M Danks
Journal:  J Paediatr Child Health       Date:  1991-06       Impact factor: 1.954

8.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

9.  Personality disorder in young women with treated phenylketonuria.

Authors:  S E Waisbren; J Zaff
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

10.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

  10 in total
  14 in total

1.  Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

Authors:  A C Ludolph; U Vetter; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 2.  Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria.

Authors:  Sandra C van Calcar; Denise M Ney
Journal:  J Acad Nutr Diet       Date:  2012-08       Impact factor: 4.910

3.  MR imaging-based volumetry in patients with early-treated phenylketonuria.

Authors:  Nadine H Pfaendner; Gitta Reuner; Joachim Pietz; Gregor Jost; Dietz Rating; Vincent A Magnotta; Alexander Mohr; Bodo Kress; Klaus Sartor; Stefan Hähnel
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

4.  Haematological findings in children with inborn errors of metabolism.

Authors:  Betul Tavil; Hatice Serapl Kalkanoglu Sivri; Turgay Coskun; Aytemiz Gurgey; Emel Ozyurek; Ali Dursun; Aysegul Tokatli; Cigdem Altay; Fatma Gumruk
Journal:  J Inherit Metab Dis       Date:  2006-08-12       Impact factor: 4.982

5.  Vitamin B12 and vitamin B6 supplementation is needed among adults with phenylketonuria (PKU).

Authors:  A M Hvas; E Nexo; J B Nielsen
Journal:  J Inherit Metab Dis       Date:  2006-02       Impact factor: 4.982

6.  Outcome implications of the International Maternal Phenylketonuria Collaborative Study (MPKUCS): 1994.

Authors:  R Koch; H Levy; W Hanley; R Matalon; B Rouse; F Trefz; F de la Cruz
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Long-term compliance with a novel vitamin and mineral supplement in older people with PKU.

Authors:  A MacDonald; P Lee; P Davies; A Daly; M Lilburn; H Gokmen Ozel; M A Preece; C Hendriksz; A Chakrapani
Journal:  J Inherit Metab Dis       Date:  2008-10-22       Impact factor: 4.982

8.  A new, low-volume protein substitute for teenagers and adults with phenylketonuria.

Authors:  A MacDonald; M Lilburn; B Cochrane; P Davies; A Daly; D Asplin; S K Hall; A Cousins; A Chakrapani; P Robinson; P Lee
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 9.  Phenylketonuria: translating research into novel therapies.

Authors:  Gladys Ho; John Christodoulou
Journal:  Transl Pediatr       Date:  2014-04

10.  Peak bone mass in patients with phenylketonuria.

Authors:  D Modan-Moses; I Vered; G Schwartz; Y Anikster; S Abraham; R Segev; Ori Efrati
Journal:  J Inherit Metab Dis       Date:  2007-03-08       Impact factor: 4.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.